[1]
|
Van Benschoten, V., Roy, C., et al. (2022) Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Transplantation and Cellular Therapy, 28, 266.e1-266.e8.
https://doi.org/10.1016/j.jtct.2022.01.009
|
[2]
|
Li, A., Bhatraju, P.K., Chen, J., et al. (2021) Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study. Transplantation and Cellular Therapy, 27, 308.e1-308.e8.
https://doi.org/10.1016/j.jtct.2020.12.010
|
[3]
|
Punatar, S., Kalantri, S.A., Chichra, A., et al. (2021) Pre-Transplant Use of Tyrosine Kinase Inhibitors and Transplant Associated Thrombotic Microangiopathy—A Single Centre Analysis of Incidence, Risk Factors and Outcomes. Bone Marrow Transplantation, 56, 1558-1562. https://doi.org/10.1038/s41409-021-01213-0
|
[4]
|
Khosla, J., Yeh, A.C., Spitzer, T.R. and Dey, B.R. (2018) Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Current Paradigm and Novel Therapies. Bone Marrow Transplantation, 53, 129-137.
https://doi.org/10.1038/bmt.2017.207
|
[5]
|
Goldberg, R.J., Nakagawa, T., Johnson, R.J. and Thurman, J.M. (2010) The Role of Endothelial Cell Injury in Thrombotic Microangiopathy. American Journal of Kidney Diseases, 56, 1168-1174.
https://doi.org/10.1053/j.ajkd.2010.06.006
|
[6]
|
Willems, E., Baron, F., Seidel, L., et al. (2010) Comparison of Thrombotic Microangiopathy after Allogeneic Hematopoietic Cell Transplantation with High-Dose or Nonmyeloablative Conditioning. Bone Marrow Transplantation, 45, 689-693. https://doi.org/10.1038/bmt.2009.230
|
[7]
|
Jodele, S., Licht, C., Goebel, J., Dixon, B.P., Zhang, K., Sivakumaran, T.A., et al. (2013) Abnormalities in the Alternative Pathway of Complement in Children with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Blood, 122, 2003-2007. https://doi.org/10.1182/blood-2013-05-501445
|
[8]
|
Qi, J., Pan, T., You, T., et al. (2022) Upregulation of HIF-1α Contributes to Complement Activation in Transplantation-Associated Thrombotic Microangiopathy. British Journal of Haematology, 199, 603-615.
https://doi.org/10.1111/bjh.18377
|
[9]
|
Ricklin, D. and Cines, D.B. (2013) TMA: Beware of Complements. Blood, 122, 1997-1999.
https://doi.org/10.1182/blood-2013-07-512707
|
[10]
|
Jan, A.S., Hosing, C., Aung, F. and Yeh, J. (2019) Ap-proaching Treatment of Transplant-Associated Thrombotic Microangiopathy from Two Directions with Eculizumab and Transitioning from Tacrolimus to Sirolimus. Transfusion, 59, 3519-3524. https://doi.org/10.1111/trf.15534
|
[11]
|
Zhao, Y., Zhang, L., Qiao, Y., et al. (2013) Heme Oxygenase-1 Prevents Cardiac Dysfunction in Streptozotocin-Diabetic Mice by Reducing Inflammation, Oxidative Stress, Apoptosis and En-hancing Autophagy. PLOS ONE, 8, e75927.
https://doi.org/10.1371/journal.pone.0075927
|
[12]
|
Tu, C.F., Tai, H.C., et al. (2010) The in Vitro Protection of Human Decay Accelerating Factor and hDAF/Heme Oxygenase-1 Transgenes in Porcine Aortic Endothelial Cells against Sera of Formosan Macaques. Transplantation Proceedings, 42, 2138-2141. https://doi.org/10.1016/j.transproceed.2010.05.104
|
[13]
|
Elemary, M., Sabry, W., Seghatchian, J. and Goubran, H. (2019) Transplant-Associated Thrombotic Microangiopathy: Diagnostic Challenges and Management Strategies. Transfusion and Apheresis Science, 58, 347-350.
https://doi.org/10.1016/j.transci.2019.04.022
|
[14]
|
Mezö, B., Horváth, O., Sinkovits, G., et al. (2020) Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation. Frontiers in Medicine (Lausanne), 7, Article ID: 569291. https://doi.org/10.3389/fmed.2020.569291
|
[15]
|
Jodele, S., Laskin, B.L., Dandoy, C.E., et al. (2015) A New Para-digm: Diagnosis and Management of HSCT-Associated Thrombotic Microangiopathy as Multi-System Endothelial In-jury. Blood Reviews, 29, 191-204.
https://doi.org/10.1016/j.blre.2014.11.001
|
[16]
|
Dandoy, C., Davies, S.M., Hirsch, R., Chima, R.S., Paff, Z., Cash, M., et al. (2014) Abnormal Echocardiography Seven Days after Stem Cell Transplant May Be an Early Indicator of Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 21, 113-118. https://doi.org/10.1016/j.bbmt.2014.09.028
|
[17]
|
El-Bietar, J., Warren, M., Dandoy, C., et al. (2015) Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 21, 1994-2001. https://doi.org/10.1016/j.bbmt.2015.06.016
|
[18]
|
Dhakal, P. and Bhatt, V.R. (2017) Is Complement Blockade an Acceptable Therapeutic Strategy for Hematopoietic Cell Transplant-Associated Thrombotic Microangiopathy? Bone Marrow Transplantation, 52, 352-356.
https://doi.org/10.1038/bmt.2016.253
|
[19]
|
Cho, B.S., Yahng, S.A., Lee, S.E., et al. (2010) Validation of Recently Proposed Consensus Criteria for Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 90, 918-926.
https://doi.org/10.1097/TP.0b013e3181f24e8d
|
[20]
|
Laskin, B.L., Goebel, J., Davies, S.M., et al. (2011) Early Clinical Indicators of Transplant-Associated Thrombotic Microangiopathy in Pediatric Neuroblastoma Patients Undergo-ing Auto-SCT. Bone Marrow Transplantation, 46, 682-689.
https://doi.org/10.1038/bmt.2010.182
|
[21]
|
Ishikawa, Y., Nishio, S., Sasaki, H., et al. (2011) Transplanta-tion-Associated Thrombotic Microangiopathy after Steroid Pulse Therapy for Polyserositis Related to Graft-versus-Host Disease. Clinical and Experimental Nephrology, 15, 179-183. https://doi.org/10.1007/s10157-010-0376-y
|
[22]
|
Ruutu, T., Barosi, G., Benjamin, R.J., et al. (2007) Diagnostic Criteria for Hematopoietic Stem Cell Transplant-Associated Microangiopathy: Results of a Consensus Process by an International Working Group. Haematologica, 92, 95-100.
https://doi.org/10.3324/haematol.10699
|
[23]
|
Rudoni, J., Jan, A., Hosing, C., Aung, F. and Yeh, J. (2018) Eculizumab for Transplant-Associated Thrombotic Microangiopathy in Adult Allogeneic Stem Cell Transplant Recipients. European Journal of Haematology, 101, 389-398.
https://doi.org/10.1111/ejh.13127
|
[24]
|
中华医学会血液学分会造血干细胞应用学组. 造血干细胞移植相关血栓性微血管病诊断和治疗中国专家共识(2021年版) [J]. 中华血液学杂志, 2021, 42(3): 177-184.
|
[25]
|
Jodele, S., Davies, S.M., Lane, A., et al. (2014) Diagnostic and Risk Criteria for HSCT-Associated Thrombotic Microangiopathy: A Study in Children and Young Adults. Blood, 124, 645-653.
https://doi.org/10.1182/blood-2014-03-564997
|
[26]
|
Fuge, R., Bird, J.M., Fraser, A., et al. (2001) The Clinical Features, Risk Factors and Outcome of Thrombotic Thrombocytopenic Purpura Occurring after Bone Marrow Trans-plantation. British Journal of Haematology, 113, 58-64.
https://doi.org/10.1046/j.1365-2141.2001.02699.x
|
[27]
|
Au, W.Y., Ma, E.S., Lee, T.L., et al. (2007) Successful Treatment of Thrombotic Microangiopathy after Haematopoietic Stem Cell Transplantation with Rituximab. British Journal of Haematology, 137, 475-478.
https://doi.org/10.1111/j.1365-2141.2007.06588.x
|
[28]
|
Carella, A.M., D’Arena, G., Greco, M.M., Nobile, M. and Cascavilla, N. (2008) Rituximab for Allo-SCT-Associated Thrombotic Thrombocytopenic Purpura. Bone Marrow Transplantation, 41, 1063-1065.
https://doi.org/10.1038/bmt.2008.25
|
[29]
|
Dhakal, P., Giri, S., Pathak, R. and Bhatt, V.R. (2017) Eculizumab in Transplant-Associated Thrombotic Microangiopathy. Clinical and Applied Thrombosis/Hemostasis, 23, 175-180. https://doi.org/10.1177/1076029615599439
|
[30]
|
Rudoni, J., Jan, A., Hosing, C., et al. (2018) Eculizumab for Transplant-Associated Thrombotic Microangiopathy in Adult Allogeneic Stem Cell Transplant Recipients. European Journal of Haematology, 101, 389-398.
https://doi.org/10.1111/ejh.13127
|
[31]
|
Kim, S.S., Patel, M., Yum, K., et al. (2015) Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Review of Pharmacologic Treatment Options. Transfusion, 55, 452-458. https://doi.org/10.1111/trf.12859
|
[32]
|
Jodele, S., Fukuda, T., Vinks, A., et al. (2014) Eculizumab Ther-apy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation, 20, 518-525.
https://doi.org/10.1016/j.bbmt.2013.12.565
|
[33]
|
Corti, P., Uderzo, C., Tagliabue, A., et al. (2002) Defibrotide as a Promising Treatment for Thrombotic Thrombocytopenic Purpura in Patients Undergoing Bone Marrow Transplantation. Bone Marrow Transplantation, 29, 542-543.
https://doi.org/10.1038/sj.bmt.1703414
|
[34]
|
Uderzo, C., Bonanomi, S., Busca, A., et al. (2006) Risk Factors and Severe Outcome in Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. Trans-plantation, 82, 638-644.
https://doi.org/10.1097/01.tp.0000230373.82376.46
|
[35]
|
Devadas, S.K., Toshniwal, M., Bagal, B., et al. (2018) Successful Treatment of Transplant Associated Thrombotic Microangiopathy (TA-TMA) with Low Dose Defibrotide. Indian Journal of Hematology and Blood Transfusion, 34, 469-473. https://doi.org/10.1007/s12288-017-0904-y
|
[36]
|
Laberko, A., Aksenova, M., Shipitsina, I., et al. (2020) Serious Hemorrhagic Complications after Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy with Defibrotide in Pediatric Patient with Myelodysplastic Syndrome. Frontiers in Pedi-atrics, 8, Article No. 155.
https://doi.org/10.3389/fped.2020.00155
|